Stifel Nicolaus Remains a Buy on Zoetis

By Ryan Adsit

In a report issued on August 30, Jonathan Block from Stifel Nicolaus reiterated a Buy rating on Zoetis (NYSE: ZTS), with a price target of $65. The company’s shares closed yesterday at $62.70, close to its 52-week high of $63.85.

According to, Block is a 5-star analyst with an average return of 18.2% and a 71.0% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Zeltiq Aesthetics.

Currently, the analyst consensus on Zoetis is Moderate Buy and the average price target is $68.78, representing a 9.7% upside.

In a report issued on August 15, Jefferies also reiterated a Buy rating on the stock with a $74 price target.

Zoetis’ market cap is currently $30.7B and has a P/E ratio of 35.42. The company has a book value ratio of 17.9019.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines, complemented by diagnostic products, genetic tests, bio devices and services, which are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company was founded in July 2012 and is headquartered in New York, NY.